5,6-Dichloropurine-1-β-D-ribofuanosyl-H-benzimidazole

• CAT Number: R003514
• CAS Number: 53-85-0
• Molecular Formula: C12H12Cl2N2O4
• Molecular Weight: 319.14
• Purity: ≥95%
• Synonyms: 5,6-Dichlorobenzimidazole 1-β-D-Ribofuranoside; 1-β-D-Ribofuranosyl-5,6-dichlorobenzimidazole; 5,6-Dichloro-1-(β-D-ribofuranosyl)benzimidazole; DRB; NSC 401575
• Target: HIV
• Solubility: Soluble in DMSO
• Storage: Store at -20°C
• IUPAC Name: (2R,3R,4S,5R)-2-(5,6-dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• InChI: InChI=1S/C12H12Cl2N2O4/c13-5-1-7-8(2-6(5)14)16(4-15-7)12-11(19)10(18)9(3-17)20-12/h1-2,4,9-12,17-19H,3H2/t9-,10-,11-,12-/m1/s1
• InChIKey: XHSQDZXAVJRBMX-DDHJBXDOSA-N
• SMILES: C1=C2C(=CC(=C1Cl)Cl)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O

5,6-Dichloropurine-1-β-D-ribofuranosyl-H-benzimidazole（Cat No.:R003514）is a synthetic nucleoside analog exhibiting potential antiviral and anticancer activities. This compound incorporates a modified purine structure, enhancing its ability to inhibit viral replication and tumor cell proliferation. Its unique configuration allows for selective targeting of nucleic acid synthesis pathways, disrupting the normal function of viral and cancerous cells. Research is ongoing to evaluate its efficacy and safety in preclinical models, with hopes of developing it as a therapeutic agent for various viral infections and malignancies, offering new avenues for treatment strategies.